🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHepatic steatosis grading on ultrasound — July 2024 Page 2

Hepatic steatosis grading on ultrasound — July 2024

traveltech_sara Sun, Mar 16, 2025 at 11:06 AM 28 replies 1,920 viewsPage 2 of 6
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Mar 16, 2025 at 12:13 PM#6
Dr.RenalNash said:
Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD).

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
Last edited: Mar 16, 2025 at 2:13 PM
45 15jennifer_SEA, tyler_CSCS, VanRx_Mike and 42 others
Reply Quote Save Share Report
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Mar 16, 2025 at 12:39 PM#7
traveltech_sara said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 340 dB/m (moderate steatosis) and stiffness 9.8 kPa (possible fibrosis). Diagnosed with NAFLD.

After 14 months: CAP dropped to 243 dB/m (minimal steatosis) and stiffness normalized to 6.1 kPa. Hepatologist says the liver is essentially healing itself as the metabolic stress resolves.

GLP-1 agonists may become first-line NASH therapy. The Phase 3 data on semaglutide for NASH is very promising.

44 14JenPlateau, SallyK_inj, CryptoCarl and 41 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Mar 16, 2025 at 1:05 PM#8
KevinCompounds said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Adding the part of the answer the thread has not reached. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

That is the short version; the long version is somebody else's post.

43 13BrianDallas92, labquiet_amy, emily_PDX and 40 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Mar 16, 2025 at 1:31 PM#9

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

42 12Dr.PathRoch, mona_PHX, andrew_nyc and 39 others
Reply Quote Save Share Report
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Mar 16, 2025 at 3:37 PM#10

OP back with an update, since a thread like this is useless without one.

Closing the loop. The answer turned out to depend on the detail I had left out of the opening post, which is a lesson about how to ask rather than about the subject.

24 22BenResearch_OR, MikeKY_noInsulin, Dr.RaviCardio and 21 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register